Johnson Fistel Begins Investigation into Metagenomi Following a Significant Drop in the Company’s Stock Price
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under the federal securities laws.
What if I purchased Metagenomi common stock? If you purchased Metagenomi common stock and suffered losses on your investment, join our investigation now:
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471
There is no cost or obligation to you.
What is Johnson Fistel investigating? On February 12, 2024, Metagenomi completed its initial public offering (IPO), selling around 6.25 million shares at $15 per share. However, less than two months later, on May 1, 2024, Metagenomi announced the mutual termination of its collaboration with Moderna.
Specifically, Johnson Fistel’s investigation seeks to determine whether the Company’s filings with the U.S. Securities and Exchange Commission in connection with its February 2024 IPO and subsequent investor communications contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company’s business, and operations.